All In Biotech

Drug Trial Radar · NCT03644485

Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients

Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients: A Randomized, Open-label, Multicenter Clinical Trial

Last checked: Nov 20, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 284 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

284

Actual

Start

Oct 21, 2018

Primary completion

Jul 15, 2022

Study completion Jul 15, 2022

Sponsor

Lead sponsor
Astellas Pharma China, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Aug 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to confirm non-inferiority of delayed Prograf treatment to standard Prograf treatment in the incidence of delayed graft function (DGF) within 1 week between the 2 immunosuppressive (IS) treatment groups: delayed or standard Prograf together with induction therapy, and then convert to Advagraf usage in donation after cardiac (or circulatory) death (DCD) kidney transplant recipients. This study will also compare the clinical outcome within 6 month post-transplant between the 2 IS treatment groups and compare the safety throughout study period between the 2 IS treatment groups.

Conditions

  • Kidney Transplant

Interventions

  • Tacrolimus immediate-release formulationDrug

    oral

  • Tacrolimus prolonged-release formulationDrug

    oral

  • Induction therapyDrug

    All participants will receive induction therapy. The dosage and administration of induction immunotherapy will be a single kind of drug determined by the investigator.

  • Mycophenolic acid drugsDrug

    All participants will receive mycophenolic acid drugs in combination with corticosteroids. The dosage and administration of mycophenolic acid will be determined by the investigator.

  • CorticosteroidsDrug

    All participants will receive corticosteroids in combination with mycophenolic acid drugs. The dosage and administration of corticosteroids will be determined by the investigator.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of delayed graft function (DGF)Time frame: Up to Day 7 after transplantation

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Site CN08608

    Beijing, China

  • Site CN08619

    Beijing, China

  • Site CN08609

    Changsha, China

  • Site CN08604

    Guangzhou, China

  • Site CN08614

    Hangzhou, China

  • Site CN08617

    Hangzhou, China

  • Site CN08610

    Nanjing, China

  • Site CN08618

    Nanjing, China

  • Site CN08612

    Shanghai, China

  • Site CN08603

    Tianjin, China

  • Site CN08621

    Wenzhou, China

  • Site CN08602

    Wuhan, China

  • Site CN08613

    Wuhan, China

  • Site CN08605

    Xi'an, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.